Drug Approval | December 18, 2025
FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Patients with BRCA mutations often face aggressive disease and poor prognosis
Patients with BRCA mutations often face aggressive disease and poor prognosis
Subscribe To Our Newsletter & Stay Updated